MEDP

SEC source: 0001567619-18-003214 · doc1.xml · nonDerivative · entry 3

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 8,895,510

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $59.49. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-18-003212 · doc1.xml · nonDerivative · entry 3

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,895,510

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $58.00 to $59.49. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-18-003214 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 8,942,288

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $59.29. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-18-003212 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,942,288

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $58.00 to $59.29. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-18-003214 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 8,989,174

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.82. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-18-003212 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,989,174

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $58.00 to $58.82. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-18-003049 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 9,027,814

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.22 to $58.57. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-18-003046 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,027,814

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $58.22 to $58.57. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-18-025028 · doc4.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,030,527

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $58.00 to $58.74. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-18-025027 · doc4.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 9,030,527

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.74. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-025028 · doc4.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,084,369

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2018.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $58.00 to $64.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-18-025027 · doc4.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 9,084,369

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $64.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-023310 · doc4.xml · nonDerivative · entry 1

Medpace Limited Partnership · CIK 0001709863 · 10% owner

Medpace GP Ltd · CIK 0001709888 · 10% owner

Cinven Capital Management (V) General Partner Ltd · CIK 0001657322 · 10% owner

Cinven Capital Management (V) Limited Partnership Inc · CIK 0001677850 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · ownership.nature: The shares of Common Stock reported herein are held of record by Medpace Limited Partnership. Cinven Capital Management (V) General Partner Limited ("Cinven MGP") is the Managing General Partner of Cinven Capital Management (V) Limited Partnership Incorporated ("GPLP"), which is the Managing General Partner of a majority of the stockholders of Medpace GP Limited ("Medpace GP"), which is the general partner of Medpace Limited Partnership. The board of directors of Medpace GP has voting and investment discretion with respect to the shares held of record by Medpace Limited Partnership. Cinven MGP, as Managing General Partner of the Managing General Partner of a majority of the stockholders of Medpace GP, indirectly controls Medpace GP.

F2 · ownership.nature: (Continued from Footnote 1) Decisions of Cinven MGP are taken by its board of directors, which is comprised of Robin Hall, Brian Linden, Hayley Tanguy, John Boothman, Rupert Dorey and William Scott. Each such director disclaims beneficial ownership of the shares reported herein.

SEC source: 0001567619-18-001191 · doc1.xml · derivative · entry 2

DAVENPORT FRED B JR · CIK 0001181154 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,710

Underlying: Common Stock · 4,710 shares

Expires 2025-08-13

F2 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-18-001194 · doc1.xml · derivative · entry 1

McCarthy Cornelius P. III · CIK 0001750355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,710

Underlying: Common Stock · 4,710 shares

Expires 2025-08-13

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0000899243-18-022044 · doc4.xml · nonDerivative · entry 1

Medpace Limited Partnership · CIK 0001709863 · 10% owner

Medpace GP Ltd · CIK 0001709888 · 10% owner

Cinven Capital Management (V) General Partner Ltd · CIK 0001657322 · 10% owner

Cinven Capital Management (V) Limited Partnership Inc · CIK 0001677850 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 5,224,997

F1 · ownership.nature: The shares of Common Stock reported herein are held of record by Medpace Limited Partnership. Cinven Capital Management (V) General Partner Limited ("Cinven MGP") is the Managing General Partner of Cinven Capital Management (V) Limited Partnership Incorporated ("GPLP"), which is the Managing General Partner of a majority of the stockholders of Medpace GP Limited ("Medpace GP"), which is the general partner of Medpace Limited Partnership. The board of directors of Medpace GP has voting and investment discretion with respect to the shares held of record by Medpace Limited Partnership. Cinven MGP, as Managing General Partner of the Managing General Partner of a majority of the stockholders of Medpace GP, indirectly controls Medpace GP.

F2 · ownership.nature: (Continued from Footnote 1) Decisions of Cinven MGP are taken by its board of directors, which is comprised of Robin Hall, Brian Linden, Hayley Tanguy, John Boothman, Rupert Dorey and William Scott. Each such director disclaims beneficial ownership of the shares reported herein.

SEC source: 0001567619-18-000253 · doc1.xml · nonDerivative · entry 3

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 351,851

F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018.

F4 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018.

F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.96 to $58.16. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-18-021486 · doc4.xml · nonDerivative · entry 3

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 489,956

F1 · kind: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018.

F1 · shares: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.84 to $59.59. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-18-021486 · doc4.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 646,325

F1 · kind: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018.

F1 · shares: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018.

F3 · price: The reported full price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.87 to $61.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-18-021486 · doc4.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 849,621

F1 · kind: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018.

F1 · shares: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.81 to $60.75. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-18-021485 · doc4.xml · nonDerivative · entry 1

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.15 to $60.28 per share. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-18-016606 · doc4.xml · nonDerivative · entry 1

Medpace Limited Partnership · CIK 0001709863 · 10% owner

Medpace GP Ltd · CIK 0001709888 · 10% owner

Cinven Capital Management (V) General Partner Ltd · CIK 0001657322 · 10% owner

Cinven Capital Management (V) Limited Partnership Inc · CIK 0001677850 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,399,997

F1 · ownership.nature: The shares of Common Stock reported herein are held of record by Medpace Limited Partnership. Cinven Capital Management (V) General Partner Limited ("Cinven MGP") is the Managing General Partner of Cinven Capital Management (V) Limited Partnership Incorporated ("GPLP"), which is the Managing General Partner of a majority of the stockholders of Medpace GP Limited ("Medpace GP"), which is the general partner of Medpace Limited Partnership. The board of directors of Medpace GP has voting and investment discretion with respect to the shares held of record by Medpace Limited Partnership. Cinven MGP, as Managing General Partner of the Managing General Partner of a majority of the stockholders of Medpace GP, indirectly controls Medpace GP.

F2 · ownership.nature: (Continued from Footnote 1) Decisions of Cinven MGP are taken by its board of directors, which is comprised of Robin Hall, Brian Linden, Hayley Tanguy, John Boothman, Rupert Dorey and William Scott. Each such director disclaims beneficial ownership of the shares reported herein.

SEC source: 0001140361-18-025168 · doc1.xml · derivative · entry 1

Carley Brian T · CIK 0001677791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,127

Underlying: Common Stock · 8,127 shares

Expires 2025-05-18

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001140361-18-025169 · doc1.xml · derivative · entry 1

Kraft Robert O. · CIK 0001558592 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,127

Underlying: Common Stock · 8,127 shares

Expires 2025-05-18

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001140361-18-025167 · doc1.xml · derivative · entry 1

Brown Bruce · CIK 0001436840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,127

Underlying: Common Stock · 8,127 shares

Expires 2025-05-18

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0000899243-18-011853 · doc4.xml · nonDerivative · entry 1

Medpace Limited Partnership · CIK 0001709863 · 10% owner

Medpace GP Ltd · CIK 0001709888 · 10% owner

Cinven Capital Management (V) General Partner Ltd · CIK 0001657322 · 10% owner

Cinven Capital Management (V) Limited Partnership Inc · CIK 0001677850 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 13,399,997

F1 · ownership.nature: The shares of Common Stock reported herein are held of record by Medpace Limited Partnership. Cinven Capital Management (V) General Partner Limited ("Cinven MGP") is the Managing General Partner of Cinven Capital Management (V) Limited Partnership Incorporated ("GPLP"), which is the Managing General Partner of a majority of the stockholders of Medpace GP Limited ("Medpace GP"), which is the general partner of Medpace Limited Partnership. The board of directors of Medpace GP has voting and investment discretion with respect to the shares held of record by Medpace Limited Partnership. Cinven MGP, as Managing General Partner of the Managing General Partner of a majority of the stockholders of Medpace GP, indirectly controls Medpace GP.

F2 · ownership.nature: (Continued from Footnote 1) Decisions of Cinven MGP are taken by its board of directors, which is comprised of Robin Hall, Brian Linden, Hayley Tanguy, John Boothman, Rupert Dorey and William Scott. Each such director disclaims beneficial ownership of the shares reported herein.

SEC source: 0001140361-18-011629 · doc1.xml · derivative · entry 2

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2025-02-28

F2 · derivative.exercise_date: The option vests on February 28, 2022, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001140361-18-011628 · doc1.xml · derivative · entry 1

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2025-02-28

F1 · derivative.exercise_date: The option vests on February 28, 2022, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001140361-18-011626 · doc1.xml · derivative · entry 1

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2025-02-28

F1 · derivative.exercise_date: The option vests on February 28, 2022, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0000899243-17-028161 · doc4.xml · nonDerivative · entry 1

Medpace Limited Partnership · CIK 0001709863 · 10% owner

Medpace GP Ltd · CIK 0001709888 · 10% owner

Cinven Capital Management (V) General Partner Ltd · CIK 0001657322 · 10% owner

Cinven Capital Management (V) Limited Partnership Inc · CIK 0001677850 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 16,399,997

F1 · ownership.nature: The shares of Common Stock reported herein are held of record by Medpace Limited Partnership. Cinven Capital Management (V) General Partner Limited ("Cinven MGP") is the Managing General Partner of Cinven Capital Management (V) Limited Partnership Incorporated ("GPLP"), which is the Managing General Partner of a majority of the stockholders of Medpace GP Limited ("Medpace GP"), which is the general partner of Medpace Limited Partnership. The board of directors of Medpace GP has voting and investment discretion with respect to the shares held of record by Medpace Limited Partnership. Cinven MGP, as Managing General Partner of the Managing General Partner of a majority of the stockholders of Medpace GP, indirectly controls Medpace GP.

F2 · ownership.nature: (Continued from Footnote 1) Decisions of Cinven MGP are taken by its board of directors, which is comprised of Robin Hall, Brian Linden, Hayley Tanguy, John Boothman, Rupert Dorey and William Scott. Each such director disclaims beneficial ownership of the shares reported herein.

SEC source: 0000899243-17-020863 · doc4.xml · nonDerivative · entry 1

Medpace Limited Partnership · CIK 0001709863 · 10% owner

Medpace GP Ltd · CIK 0001709888 · 10% owner

Cinven Capital Management (V) General Partner Ltd · CIK 0001657322 · 10% owner

Cinven Capital Management (V) Limited Partnership Inc · CIK 0001677850 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 20,999,997

F1 · ownership.nature: The shares of Common Stock reported herein are held of record by Medpace Limited Partnership. Cinven Capital Management (V) General Partner Limited ("Cinven MGP") is the Managing General Partner of Cinven Capital Management (V) Limited Partnership Incorporated ("GPLP"), which is the Managing General Partner of a majority of the stockholders of Medpace GP Limited ("Medpace GP"), which is the general partner of Medpace Limited Partnership. The board of directors of Medpace GP has voting and investment discretion with respect to the shares held of record by Medpace Limited Partnership. Cinven MGP, as Managing General Partner of the Managing General Partner of a majority of the stockholders of Medpace GP, indirectly controls Medpace GP.

F2 · ownership.nature: (Continued from Footnote 1) Decisions of Cinven MGP are taken by its board of directors, which is comprised of Robin Hall, Brian Linden, Hayley Tanguy, John Boothman, Rupert Dorey, William Scott and Matthew Chick as Alternate Director. Each such director disclaims beneficial ownership of the shares reported herein.

SEC source: 0001567619-18-000255 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,145,510

F2 · kind: Issuer shares were disposed of by the Reporting Person through an in-kind exchange of Class B units of the Reporting Person acquired by an individual.

SEC source: 0001567619-18-000253 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 9,145,510

F3 · kind: Issuer shares were disposed of by MPI through an in-kind exchange of Class B units of MPI acquired by an individual.

F2 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001140361-18-011629 · doc1.xml · nonDerivative · entry 1

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,407

F1 · price: Shares acquired by an in-kind exchange of Issuer shares for investment units of Medpace Investors, LLC originally acquired by the Reporting Person upon exercise of Issuer options. The options, once exercised, were immediately exchanged for investment units in Medpace Investors, LLC as required by the Medpace Holdings, Inc. 2014 Equity Incentive Plan.

SEC source: 0001567619-18-000255 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,182,547

F1 · kind: Issuer shares were disposed of by the Reporting Person through an in-kind exchange of incentive units of the Reporting Person acquired by employees of entities affiliated with the Issuer.

SEC source: 0001567619-18-000253 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 9,182,547

F1 · kind: Issuer shares were disposed of by Medpace Investors, LLC ("MPI) through an in-kind exchange of incentive units of MPI acquired by employees of entities affiliated with the Issuer.

F2 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-17-016948 · doc4.xml · nonDerivative · entry 1

Fifth Cinven Fund (No. 1) Limited Partnership · CIK 0001538517 · 10% owner

Fifth Cinven Fund (No. 2) Limited Partnership · CIK 0001548370 · 10% owner

Fifth Cinven Fund (No. 3) Limited Partnership · CIK 0001548369 · 10% owner

Fifth Cinven Fund (No. 4) Limited Partnership · CIK 0001548368 · 10% owner

Fifth Cinven Fund (No. 5) Limited Partnership · CIK 0001560588 · 10% owner

Fifth Cinven Fund (No. 6) Limited Partnership · CIK 0001573041 · 10% owner

Fifth Cinven Fund Co-Investment Partnership · CIK 0001677857 · 10% owner

Cinven Manco S.A.R.L. · CIK 0001677872 · 10% owner

Fifth Cinven Fund FCP-SIF · CIK 0001677859 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · kind: Represents a transfer by the Cinven Shareholders (as defined below) to Medpace Limited Partnership in exchange for limited partnership interests in Medpace Limited Partnership in connection with the execution of a margin loan agreement by Medpace Limited Partnership.

F2 · ownership.nature: Prior to the transactions reported herein, included 3,641,240 shares held by Fifth Cinven Fund (No. 1) Limited Partnership ("LP1"), 3,229,699 shares held by Fifth Cinven Fund (No. 2) Limited Partnership ("LP2"), 3,889,854 shares held by Fifth Cinven Fund (No. 3) Limited Partnership ("LP3"), 3,379,103 shares held by Fifth Cinven Fund (No. 4) Limited Partnership ("LP4"), 1,403,731 shares held by Fifth Cinven Fund (No. 5) Limited Partnership ("LP5"), 3,284,802 shares held by Fifth Cinven Fund (No. 6) Limited Partnership ("LP6" and, together with LP1, LP2, LP3, LP4 and LP5, the "Limited Partnerships"), 3,758,169 shares held by Fifth Cinven Fund FCP-SIF ("FCP"), which is managed and controlled by Cinven Manco S.A.R.L. ("Manco"), and 413,399 shares held by Fifth Cinven Fund Co-Investment Partnership ("CIP" and, together with the Limited Partnerships and FCP, the "Cinven Shareholders").

F3 · ownership.nature: Each of the Limited Partnerships is managed and controlled by Cinven Capital Management (V) Limited Partnership Incorporated ("GPLP"), their Managing General Partner. Cinven Capital Management (V) General Partner Limited ("Cinven MGP") is the Managing General Partner of GPLP. FCP is managed and controlled by Cinven Manco S.A.R.L. ("Manco"). Cinven MGP also exercises control over the shares held by each of FCP and CIP, which are subject to contractual commitments that each invest and divest side-by-side with the Limited Partnerships. Voting and investment determinations with respect to the shares held by the Cinven Shareholders are made by the majority vote of the board of directors of Cinven MGP, comprised of Brian Linden, Hayley Tanguy, John Boothman, Robin Hall, Rupert Dorey and William Scott. Each such director disclaims beneficial ownership of such shares.

SEC source: 0001140361-17-021939 · doc1.xml · derivative · entry 1

Carley Brian T · CIK 0001677791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,782

Underlying: Common Stock · 13,782 shares

Expires 2024-05-19

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001140361-17-021944 · doc1.xml · derivative · entry 1

Kraft Robert O. · CIK 0001558592 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,782

Underlying: Common Stock · 13,782 shares

Expires 2024-05-19

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001140361-17-021934 · doc1.xml · derivative · entry 1

Brown Bruce · CIK 0001436840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,782

Underlying: Common Stock · 13,782 shares

Expires 2024-05-19

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0000899243-17-011885 · doc4.xml · derivative · entry 2

BUCKNELL PENELOPE J · CIK 0001677224 · VP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,814

Underlying: Common Stock · 3,000 shares

Expires 2021-07-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vests in four equal annual installments over a four year period beginning on July 7, 2014.

SEC source: 0000899243-17-011885 · doc4.xml · nonDerivative · entry 1

BUCKNELL PENELOPE J · CIK 0001677224 · VP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-021289 · doc4.xml · derivative · entry 1

BUCKNELL PENELOPE J · CIK 0001677224 · VP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: COMMON STOCK · 5,000 shares

Expires 2024-03-15

F1 · derivative.exercise_date: The option vests on March 15, 2021, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001209191-17-021296 · doc4.xml · derivative · entry 1

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: COMMON STOCK · 20,000 shares

Expires 2024-03-15

F1 · derivative.exercise_date: The option vests on March 15, 2021, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001209191-17-021293 · doc4.xml · derivative · entry 1

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: COMMON STOCK · 5,000 shares

Expires 2024-03-15

F1 · derivative.exercise_date: The option vests on March 15, 2021, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001209191-17-021292 · doc4.xml · derivative · entry 1

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: COMMON STOCK · 20,000 shares

Expires 2024-03-15

F1 · derivative.exercise_date: The option vests on March 15, 2021, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001209191-16-148228 · doc4.xml · derivative · entry 1

Brown Bruce · CIK 0001436840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires 2023-11-01

F1 · derivative.exercise_date: One-twelfth (1/12th) of the option vests on November 1, 2016. Thereafter, one-twelfth (1/12th) of the option vests on the first day of each calendar month, subject to continued service on the board of directors of the Issuer through such dates.